Bulletin
Investor Alert

London Markets Open in:

press release

Dec. 21, 2020, 8:50 a.m. EST

Psychedelics Industry Gearing Up For an Even Bigger 2021

FN Media Group Presents Microsmallcap.com Market Commentary

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Investments continued flowing into the psychedelic medicine sector this year and will likely continue in 2021 as mental illness cases rise across the globe. The World Health Organization (WHO) estimates that 700 million cases of mental and neurological disorders are reported annually, accounting for 13% of global disease burden. Of course, these are only reported cases, so the number is likely much higher and will likely rise further due to the ongoing health crisis. Luckily, growing awareness around mental illness has led to a slew of research and development for effective novel treatments to help combat the growing mental health crisis. Psychedelic medicine for mental illness is one area that has gained the spotlight after Johnson & Johnson's /zigman2/quotes/201724570/composite JNJ +0.10% severe depression drug was handed approval. Now, a number of psychedelic-focused companies like Mydecine Innovations Group Inc. /zigman2/quotes/203737825/delayed CA:MYCO -10.00% (MYCOF) , COMPASS Pathways Plc /zigman2/quotes/204069138/composite CMPS -3.79% , Tonix Pharmaceuticals /zigman2/quotes/201815757/composite TNXP -2.40% , and Numinus Wellness Inc. (neo:NUMI) /zigman2/quotes/204558261/delayed CA:NUMI -12.00% (otcpk:LKYSF) are joining the fight against mental illness with a variety of promising, psychedelic-based treatments.

Biopharma and life sciences company Mydecine Innovations Group is focused on developing and commercializing innovative solutions to treat mental health problems and enhance well being. Since the beginning of 2020, the company has hit several significant milestones to help progress its robust pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems.

Mydecine Innovations Edges Towards FDA Filing

Sentiments toward psychedelic-derived medicines have evolved significantly in the last couple of years, especially following the US Food and Drug Administration's (FDA) approval of  Johnson & Johnson's /zigman2/quotes/201724570/composite JNJ +0.10% Ketamine-like drug treatment for severe depression in March 2019. The FDA approved Spravato as a fast-acting treatment for patients with hard-to-treat depression and it became the first of several psychoactive substances moving through the US regulatory process. The administration has since granted Breakthrough Therapy Designation to two psychedelic treatments, paving the way for others to follow suit.

Mydecine Innovations Group just announced that it has partnered with ProPharma Group to proceed with the FDA filing and approval of its drug development platform and various stage clinical trials. ProPharma is the leading provider of regulatory and compliance services to the pharmaceutical, biotech, and medical device industries with "a strong track record of working with life sciences and biopharma companies to ensure full compliance with all FDA regulations, including all necessary steps for eventual global federal approvals."

Earlier this month, Mydecine Innovations reached another exciting milestone by completing its first commercial harvest of 20 kilograms of psilocybin mushrooms at its research and cultivation facility in Jamaica. The company is now preparing to export the harvest to its Canadian cGMP Facility, which holds a Health Canada schedule 1 Dealer's License, allowing for legal import.

Once Mydecine's facility receives the psilocybin mushrooms, they will be extracted, refined, and turned into a cGMP product that can be used for controlled therapeutic purposes. The final product will be available for purchase by licensed institutions and companies conducting clinical research of these compounds to treat various health conditions like anxiety, addiction, depression, and PTSD. Portions of the harvest will also be kept for Mydecine's proprietary genetic, pharmacology, and clinical research, including psilocybin-assisted psychotherapy to treat PTSD in veterans and frontline workers.

Another company looking to combat PTSD is Tonix Pharmaceuticals /zigman2/quotes/201815757/composite TNXP -2.40% , although it isn't using psychedelic compounds in its formulation like Mydecine . The company began studying TNX-601 (tianeptine oxalate) for the treatment of PTSD in September 2019. However, Tonix hit a speedbump in its Phase III RECOVERY study in February 2020 and decided to stop enrollment in the study following inadequate results. However, Tonix has since gone back to the drawing board and recently outlined a new statistical method to analyze future PTSD drug studies.

Growing Number of Psychedelic Companies Entering the Public Markets

The psychedelic drugs market is forecast to grow at a CAGR of 16.3% to reach $6.85 billion by 2027, fueled by the growing acceptance of psychedelic-derived meds to treat mental health coupled with the rising prevalence of mental disorders like depression and anxiety. Loosening legislation is also favoring the psychedelics market, leading to a growing number of psychedelic-focused pharma companies entering the public markets and bringing in investment dollars.

Integrated mental health company Numinus Wellness Inc. (neo:NUMI) /zigman2/quotes/200445894/delayed LKYSF -10.94% joined the TSX Venture Exchange in September 2020 after getting the green light from Health Canada to produce and extract psilocybin from mushrooms and closing an oversubscribed $4.6 million offering. In December, the company announced a $10 million bought deal offering, which was increased to $15 million two days later, and completed the first legal extraction of psilocybe mushrooms.

COMPASS Pathways Plc /zigman2/quotes/204069138/composite CMPS -3.79%  also joined the public markets in September after closing an astounding $146.6 million initial public offering (IPO). The listing came nearly two years after the company was handedFDA Breakthrough Therapy designation for its psilocybin therapy for treatment-resistant depression. On November 12, Compass announced its Q3 results, highlighting the steady progress in its Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression and the opening of a new trial site in Berlin, Germany. The company also joined an international collaboration to accelerate drug discovery in mental health care.

Mydecine Innovations Group  has also inked a partnership agreement this year with Applied Pharmaceutical Innovation to advance its research and development efforts for mental health care solutions. This partnership helps to put Mydecine ahead of the curve in this innovative market.

For more information Mydecine Innovations Group Inc. (MYCOF) /zigman2/quotes/203737825/delayed CA:MYCO -10.00% , please visit this link.

Disclaimer:  Microsmallcap.com (MSC) is the source of the Article and content set forth above. MSC owns and operates Streetsignals.com.  References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Mydecine Innovations Group Inc.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

Media Contact:

FN Media Group, LLC
info@financialnewsmedia.com  
+1(561)325-8757

Cision
View original content: http://www.prnewswire.com/news-releases/psychedelics-industry-gearing-up-for-an-even-bigger-2021-301196567.html

SOURCE Microsmallcap.com

COMTEX_376593879/2454/2020-12-21T08:50:07

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2020 PR Newswire. All rights reserved

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 162.76
+0.17 +0.10%
Volume: 9.72M
Feb. 25, 2021 4:00p
P/E Ratio
29.52
Dividend Yield
2.48%
Market Cap
$427.40 billion
Rev. per Employee
$613,918
loading...
/zigman2/quotes/203737825/delayed
CA : Canadian Securities Exchange
$ 0.45
-0.05 -10.00%
Volume: 3.57M
Feb. 25, 2021 3:59p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$87.69 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/204069138/composite
US : U.S.: Nasdaq
$ 48.21
-1.90 -3.79%
Volume: 309,548
Feb. 25, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.80 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/201815757/composite
US : U.S.: Nasdaq
$ 1.22
-0.03 -2.40%
Volume: 27.42M
Feb. 25, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$404.89 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/204558261/delayed
CA : Canada: TSX Venture
$ 1.54
-0.21 -12.00%
Volume: 1.84M
Feb. 25, 2021 5:40p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$237.85 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 162.76
+0.17 +0.10%
Volume: 9.72M
Feb. 25, 2021 4:00p
P/E Ratio
29.52
Dividend Yield
2.48%
Market Cap
$427.40 billion
Rev. per Employee
$613,918
loading...
/zigman2/quotes/201815757/composite
US : U.S.: Nasdaq
$ 1.22
-0.03 -2.40%
Volume: 27.42M
Feb. 25, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$404.89 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/200445894/delayed
US : U.S.: OTC
$ 1.23
-0.15 -10.94%
Volume: 1.01M
Feb. 25, 2021 3:58p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$189.29 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/204069138/composite
US : U.S.: Nasdaq
$ 48.21
-1.90 -3.79%
Volume: 309,548
Feb. 25, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.80 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/203737825/delayed
CA : Canadian Securities Exchange
$ 0.45
-0.05 -10.00%
Volume: 3.57M
Feb. 25, 2021 3:59p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$87.69 million
Rev. per Employee
N/A
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.